Table 1.
Characteristics of the patient population reported in this study [n (%)]
| Gender | Male | 31 (73.8) |
| Female | 11 (26.2) | |
| Histology | Clear cell | 32 (76.2) |
| Papillary | 7 (16.7) | |
| Chromophobe | 1 (2.4) | |
| SDHB-associated | 1 (2.4) | |
| NOS | 1 (2.4) | |
| Prior treatment lines | TKI | 42 (100) |
| TKI only | 29 (69.0) | |
| TKI+ immunotherapy | 6 (14.3) | |
| TKI+ everolimus | 5 (11.9) | |
| TKI+ everolimus +immunotherapy | 3 (7.1) | |
| ECOG performance status (all patients) | 0 | 17 (40.5) |
| 1 | 12 (28.6) | |
| 2 | 12 (28.6) | |
| 3 | 0 | |
| 4 | 1 (2.4) | |
| ECOG performance status (dose-escalated patients) | 0 | 15 (51.7) |
| 1 | 9 (31.0) | |
| 2 | 5 (17.2) | |
| 3 | 0 | |
| 4 | 0 | |
| ECOG performance status (non-dose-escalated patients) | 0 | 2 (15.4) |
| 1 | 3 (23.1) | |
| 2 | 7 (53.8) | |
| 3 | 0 | |
| 4 | 1 (7.7) |
ECOG, Eastern Cooperative Oncology Group; NOS, histology not otherwise specified (non-clear cell)); SDHB, succinate dehydrogenase B; TKI, tyrosine kinase inhibitor other than axitinib.